Company: TEM
Filing Date: 2025-02-24
Form Type: 10-K
Source: 0000950170-25-025603
Chunk: 305

Company: Tempus AI, Inc.
Filing Date: 2025-02-24
Form: 10-K
Item: Item 8
Chunk 305
---
 warrant

    —

    —

    109,459

    0

    —

    —

    —

    —

    —

    —

    (173
    )
     
    —

    —

    (173
    )

    Stock-based compensation expense

    —

    —

    —

    —

    —

    —

    —

    —

    —

    —

    534,138

    —

    —

    534,138

    Foreign currency translation adjustment

    —

    —

    —

    —

    —

    —

    —

    —

    —

    —

    —

    —

    89

    89

    Net loss

    —

    —

    —

    —

    —

    —

    —

    —

    —

    —

    —

    (705,809
    )
     
    —

    (705,809
    )

    Balance at December 31, 2024

    —

    $
    —

    157,076,972
     
    $
    16

    5,043,789
     
    $
    1

    —
     
    $
    —

    (145,466
    )
    $
    (3,602
    )
    $
    2,210,664
     
    $
    (2,150,834
    )
    $
    94
     
    $
    56,339

The accompanying notes are an integral part of these consolidated financial statements. 

145

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 

1.DESCRIPTION OF BUSINESS Company Information Tempus AI, Inc., together with the subsidiaries through which it conducts business (the “Company” or "Tempus"), is a healthcare technology company focused on bringing artificial intelligence and machine learning to healthcare in order to improve the care of patients across multiple diseases. The Company combines the results of laboratory tests with other multimodal datasets to improve patient care by supporting all parties in the healthcare ecosystem, including physicians, researchers, payers, and pharmaceutical companies. The Company primarily derives revenue from selling comprehensive genetic testing to physicians and large academic research institutions, licensing data to third parties, matching patients to clinical trials, and related services. The Company, based in Chicago, Illinois, was founded by Eric P. Lefkofsky, the Company’s CEO and Executive Chairman, and evolved from a business Mr. Lefkofsky founded called Bioin. Bioin originally was established as a limited liability company. Effective September 21, 2015